Discontinued — last reported Q3 '25
Redeemable NCI
Quest Diagnostics Redeemable NCI decreased by 1.3% to $79.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.5%, from $81.00M to $79.00M. Over 5 years (FY 2020 to FY 2025), Redeemable NCI shows relatively stable performance with a -0.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase indicates higher potential future cash obligations to minority partners, which may impact liquidity and capital allocation flexibility.
Detailed definition
This represents equity interests in subsidiaries held by third parties that include redemption features, such as a manda...
Peer comparison
Often found in companies with complex joint venture structures or partially owned infrastructure projects; peers report this outside of permanent equity.
redeemable_noncontrolling_interestsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $78.00M | $79.00M | $79.00M | $78.00M | $77.00M | $77.00M | $77.00M | $77.00M | $77.00M | $76.00M | $76.00M | $77.00M | $79.00M | $80.00M | $83.00M | $81.00M | $81.00M | $81.00M | $80.00M | $79.00M |
| QoQ Change | — | +1.3% | +0.0% | -1.3% | -1.3% | +0.0% | +0.0% | +0.0% | +0.0% | -1.3% | +0.0% | +1.3% | +2.6% | +1.3% | +3.8% | -2.4% | +0.0% | +0.0% | -1.2% | -1.3% |
| YoY Change | — | — | — | — | -1.3% | -2.5% | -2.5% | -1.3% | +0.0% | -1.3% | -1.3% | +0.0% | +2.6% | +5.3% | +9.2% | +5.2% | +2.5% | +1.3% | -3.6% | -2.5% |
Redeemable NCI at Other Companies
Frequently Asked Questions
- What is Quest Diagnostics's redeemable nci?
- Quest Diagnostics (DGX) reported redeemable nci of $79.00M in Q1 2026.
- How has Quest Diagnostics's redeemable nci changed year-over-year?
- Quest Diagnostics's redeemable nci decreased by 2.5% year-over-year, from $81.00M to $79.00M.
- What is the long-term trend for Quest Diagnostics's redeemable nci?
- Over 5 years (2020 to 2025), Quest Diagnostics's redeemable nci has grown at a -0.5% compound annual growth rate (CAGR), from $82.00M to $80.00M.
- What does redeemable nci mean?
- Ownership stakes held by others in a subsidiary that the company may be required to buy back in the future.